Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-iNK
- Development stage
- Preclinical
- Lead developer
- CellOrigin Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-iNK is an allogeneic, 'off-the-shelf' cancer immunotherapy being developed by CellOrigin Biotechnology. The therapy is composed of Natural Killer (NK) cells derived from induced pluripotent stem cells (iPSCs) that have been genetically engineered to express a Chimeric Antigen Receptor (CAR). This CAR is designed to direct the NK cells to specifically recognize and eliminate tumor cells. By utilizing an iPSC-based platform, the therapy aims to provide a uniform, scalable, and readily available alternative to autologous cell therapies, which are often limited by manufacturing complexity and patient-specific variability. The program is primarily focused on the treatment of solid tumors and is administered via intravenous injection.
- Other names
- iPSC-derived CAR-NK cellsCAR-engineered iPSC-derived NK cellsCellOrigin CAR-iNK
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)CD19 (B lymphocyte antigen CD19)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on CAR-iNK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-iNK.